Painful crisis is the most common cause of recurrent morbidity in sickle cell disease (SCD), accounting for approximately 90% of SCD-related admissions. Current management emphasizes prophylaxis by avoiding precipitating factors (cold, stress, infection, altitude, etc), maintenance of fluid balance, and the use of hydroxyurea in severely affected persons. During crisis, analgesia is achieved by using oral and parenteral nonsteroidal anti-inflammatory drugs and opioids.1 In the December 1953 issue of The Journal, Smith et al at Kings County Hospital in Brooklyn, New York, reported on the use of tolazoline (Priscoline, Novartis) an α-adrenergic blocking agent, in seven children with SCD who presented with moderate to severe pain. Their rationale for using this vasodilator agent was based on its previous success in treating moderate to severe pain associated with poliomyelitis. The children in this study ranged in age from 3 to 11 years. Only two had previously been diagnosed with SCD. In the first case, a 5-year-old presented with severe pain in both knees. “Following intravenous administration of the drug, there was almost instantaneous relief from the pain in the extremities.” Significant improvement of the pain was achieved in all 7 patients, and they concluded that although the drug was more effective in visceral pain compared with bone and joint pain, “Priscoline definitely shortened the period of disability in the patients treated.” They postulated that the drug helped reverse the vascular component of the crisis.